So excited to finally share the latest from our group just published in @CellCellPress describing a next-generation trivalent COVID-19 vaccine that is designed to protect against all variants, and is delivered mucosally 1/n
https://twitter.com/CellCellPress/status/1491143182830092288
This was a huge @McMasterU team effort, co-led with my incredibly talented colleagues, Dr. Zhou Xing and Dr. Brian Lichty. This vaccine is now in Phase I clinical trial, led by @inhaled_cov_vax 2/n
The real heroes behind this incredible story are the trainees who worked tirelessly to get this done on an unbelievably short timeline. Dr. Sam Afkhami from the Xing group and Mike D’Agostino from my group are co-first authors of the study
We show that mucosal vaccination is superior to conventional i.m. vaccination in protecting against #SARS-CoV-2 and #VOCs. Protection is mediated by a combination of antibodies, T cells, and trained innate immunity - all of which are required for optimal protection
This study was funded by @CIHR_ICRH , and is an excellent example of the unique culture and enabling infrastructure provided by @MacGlobalNexus that allowed us to address a very complex problem requiring multidisciplinary expertise
• • •
Missing some Tweet in this thread? You can try to
force a refresh
